Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.
Event:
ESC Congress 2023
Topic:
Pharmacotherapy
Session:
Arterial occlusive disease: a chronic pandemic needing attention to detail